Correlation between the triglyceride-to-high-density lipoprotein cholesterol ratio and other unconventional lipid parameters with the risk of prediabetes and Type 2 diabetes in patients with coronary heart disease: a RCSCD-TCM study in China.
Yang T, Liu Y, Li L, Zheng Y, Wang Y, Su J, Yang R, Luo M, Yu C.
Cardiovasc Diabetol. 2022 Jun 3;21(1):93. doi: 10.1186/s12933-022-01531-7.
Intensified glycemic control by HbA1c for patients with coronary heart disease and Type 2 diabetes: a review of findings and conclusions.
Chen J, Yin D, Dou K.
Cardiovasc Diabetol. 2023 Jun 22;22(1):146. doi: 10.1186/s12933-023-01875-8.
Evidence and Potential Mechanisms of Traditional Chinese Medicine for the Adjuvant Treatment of Coronary Heart Disease in Patients with Diabetes Mellitus: A Systematic Review and Meta-Analysis with Trial Sequential Analysis.
Wei Y, Ding QY, Yeung C, Huang YS, Zhang BX, Zhang LL, Miao RY, Di S, Zhao LH, Tong XL.
J Diabetes Res. 2022 Aug 31;2022:2545476. doi: 10.1155/2022/2545476. eCollection 2022.
Differences in HDL-related coronary heart disease risk between individuals with and without diabetes.
Chen JX, Lu Q, Geng T, Wang Y, Wang Y, Li R, Xia PF, Guo KQ, Yang K, Tong WW, Liu G, Pan A, Liao YF.
Atherosclerosis. 2024 Oct;397:118553. doi: 10.1016/j.atherosclerosis.2024.118553. Epub 2024 Aug 10.
Effect of acarbose on cardiovascular events and new-onset diabetes in patients with coronary heart disease and impaired glucose tolerance.
Wei Y, Xu W.
Future Cardiol. 2019 Mar;15(2):127-133. doi: 10.2217/fca-2018-0062. Epub 2019 Feb 22.
Disease patterns of coronary heart disease and type 2 diabetes harbored distinct and shared genetic architecture.
Xiao H, Ma Y, Zhou Z, Li X, Ding K, Wu Y, Wu T, Chen D.
Cardiovasc Diabetol. 2022 Dec 9;21(1):276. doi: 10.1186/s12933-022-01715-1.
Reducing coronary heart disease associated with type 2 diabetes: lifestyle intervention and treatment of dyslipidaemia.
Tuomilehto J.
Diabetes Res Clin Pract. 2003 Jul;61 Suppl 1:S27-34. doi: 10.1016/s0168-8227(03)00125-6.
Identification of coronary heart disease in asymptomatic individuals with diabetes mellitus: to screen or not to screen.
Bravo PE, Psaty BM, Di Carli MF, Branch KR.
Colomb Med (Cali). 2015 Mar 30;46(1):41-6. eCollection 2015 Jan-Mar.
Telomere length as biomarker of nutritional therapy for prevention of type 2 diabetes mellitus development in patients with coronary heart disease: CORDIOPREV randomised controlled trial.
Ojeda-Rodriguez A, Rangel-Zuñiga OA, Arenas-de Larriva AP, Gutierrez-Mariscal FM, Torres-Peña JD, Romero-Cabrera JL, Podadera-Herreros A, García-Fernandez H, Porras-Pérez E, Luque RM, Kales SN, Perez-Martinez P, Delgado-Lista J, Yubero-Serrano EM, Lopez-Miranda J.
Cardiovasc Diabetol. 2024 Mar 16;23(1):98. doi: 10.1186/s12933-024-02175-5.
Controversies in management of diabetes in patients with coronary heart disease.
Abdella NA.
Med Princ Pract. 2002;11 Suppl 2:69-74. doi: 10.1159/000066410.
